Heparin-binding EGF-like growth factor (HBEGF) mRNA (HBEGF mRNA)

Heparin-binding EGF-like growth factor (HBEGF) is a member of the epidermal growth factor family that plays a pivotal role in various physiological processes, including wound healing, cardiac development, and angiogenesis (UniProt Q99075). It is synthesized as a membrane-anchored precursor (proHB-EGF) that can be cleaved by ADAM proteases to release a soluble form (sHB-EGF), both of which activate the EGFR (ErbB1) and ErbB4 receptors (PubMed: 16226706). In pathological contexts, HBEGF mRNA is frequently overexpressed in several malignancies, such as ovarian, breast, and gastric cancers, where it promotes tumor cell proliferation, survival, and resistance to chemotherapy (PubMed: 22431921). Furthermore, HBEGF serves as the primary cellular receptor for diphtheria toxin, facilitating its entry into cells (NCBI Gene: 1839). Therapeutic strategies targeting HBEGF mRNA, such as siRNA and antisense oligonucleotides, are being explored to downregulate its expression and inhibit oncogenic signaling (PubMed: 18483245). While no mRNA-specific drugs are currently FDA-approved, the protein product is targeted by agents like CRM197, a non-toxic mutant of diphtheria toxin (PubMed: 21833625). Targeting the mRNA directly offers the advantage of preventing the synthesis of both the membrane-bound and soluble forms of the protein. However, safety concerns include potential cardiac toxicity, as HBEGF is essential for maintaining normal heart function. Monitoring HBEGF mRNA levels can serve as a biomarker for patient selection in clinical trials. Overall, HBEGF mRNA represents a promising but challenging target in precision oncology and cardiovascular medicine.

Other names

Heparin-binding EGF-like growth factorHB-EGFDiphtheria toxin receptorDTRDTSHEGFL

Inhibition of translation or degradation of mRNA via RNA interference or antisense mechanisms; neutralization of the resulting protein product.